Literature DB >> 22460963

Discordance between CD4+ T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis.

Cassidy W Claassen1, Marie Diener-West, Shruti H Mehta, David L Thomas, Gregory D Kirk.   

Abstract

BACKGROUND: Cirrhosis of the liver can induce splenic sequestration of peripheral blood cells, recently suggested to reduce the number but not percentage of circulating CD4(+) T cells in persons uninfected with human immunodeficiency virus (HIV). We investigated whether earlier stages of liver fibrosis prior to cirrhosis were associated with discordance between CD4 count (CD4N) and CD4 percentage (CD4%) in HIV-infected patients.
METHODS: In cross-sectional analysis of 287 HIV-infected participants of the AIDS Linked to the Intravenous Experience cohort, we evaluated CD4N, CD4%, and transient elastography staging of liver fibrosis. High CD4(+) lymphocyte discordance was defined as higher CD4% relative to CD4N based on accepted clinical cutoffs; multivariable logistic regression was used to determine covariates associated with discordance.
RESULTS: Of 287 participants, 99 (34.4%) had high CD4(+) discordance, which increased to 76% of 114 participants with marked lymphopenia (total lymphocyte count [TLC] ≤1200 cells/μL). In multivariable analysis, the odds of having high CD4(+) discordance was increased in persons with significant liver fibrosis compared to those without fibrosis (odds ratio, 1.69; 95% confidence interval [CI], .95-2.96); the odds ratio of discordance increased to 2.66 (95% CI, 1.11-6.40) among the subset of participants with TLC ≤1200 cells/μL. The odds for discordance associated with cirrhosis were of similar magnitude as those observed with significant fibrosis.
CONCLUSIONS: In HIV-infected persons, liver fibrosis is associated with discordant peripheral CD4(+) lymphocyte results, especially in the setting of marked lymphopenia. Clinicians should also consider CD4% when interpreting absolute CD4(+) counts of HIV-infected persons with known or suspected liver disease, particularly if TLC is <1200 cells/μL.

Entities:  

Mesh:

Year:  2012        PMID: 22460963      PMCID: PMC3404711          DOI: 10.1093/cid/cis294

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  50 in total

1.  Peripheral blood count abnormalities among patients with hepatitis C in the United States.

Authors:  Michael B Streiff; Shruti Mehta; David L Thomas
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

2.  CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men.

Authors:  J Burcham; M Marmor; N Dubin; B Tindall; D A Cooper; G Berry; R Penny
Journal:  AIDS       Date:  1991-04       Impact factor: 4.177

3.  Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection.

Authors:  Gregory D Kirk; Jacquie Astemborski; Shruti H Mehta; Chuck Spoler; Cedric Fisher; Danisha Allen; Yvonne Higgins; Richard D Moore; Nezem Afdhal; Michael Torbenson; Mark Sulkowski; David L Thomas
Journal:  Clin Infect Dis       Date:  2009-04-01       Impact factor: 9.079

4.  Long-term follow-up of hemophiliacs with lymphocytopenia or thrombocytopenia.

Authors:  M E Eyster; D A Whitehurst; P M Catalano; C W McMillan; S H Goodnight; C K Kasper; J C Gill; L M Aledort; M W Hilgartner; P H Levine
Journal:  Blood       Date:  1985-12       Impact factor: 22.113

5.  Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection.

Authors:  Kelly A Gebo; Joel E Gallant; Jeanne C Keruly; Richard D Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2004-08-15       Impact factor: 3.731

6.  Effects of HCV co-infection on apoptosis of CD4+ T-cells in HIV-positive patients.

Authors:  Christian Körner; Benjamin Krämer; Daniela Schulte; Martin Coenen; Stefan Mauss; Gerd Fätkenheuer; Johannes Oldenburg; Jacob Nattermann; Jürgen K Rockstroh; Ulrich Spengler
Journal:  Clin Sci (Lond)       Date:  2009-05-14       Impact factor: 6.124

7.  Idiopathic CD4+ T-lymphocytopenia in HIV seronegative men with hemophilia and sex partners of HIV seropositive men. Multicenter Hemophilia Cohort Study.

Authors:  T R O'Brien; L Diamondstone; M W Fried; L M Aledort; S Eichinger; M E Eyster; M W Hilgartner; G White; A M Di Bisceglie; J J Goedert
Journal:  Am J Hematol       Date:  1995-07       Impact factor: 10.047

8.  Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis?

Authors:  Marco Bongiovanni; Andrea Gori; Alessandro Cozzi Lepri; Andrea Antinori; Andrea de Luca; Gabriella Pagano; Alessandro Chiodera; Massimo Puoti; Antonella d'Arminio Monforte
Journal:  Clin Infect Dis       Date:  2007-08-01       Impact factor: 9.079

9.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

Authors:  J L Fahey; J M Taylor; R Detels; B Hofmann; R Melmed; P Nishanian; J V Giorgi
Journal:  N Engl J Med       Date:  1990-01-18       Impact factor: 91.245

10.  CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells/mm3.

Authors:  Marguerite Guiguet; Eric Kendjo; Guislaine Carcelain; Sophie Abgrall; Murielle Mary-Krause; Pierre Tattevin; Yazdan Yazdanpanah; Dominique Costagliola; Xavier Duval
Journal:  Antivir Ther       Date:  2009
View more
  7 in total

1.  [Not Available].

Authors:  Mark Hull; Pierre Giguère; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Côté; Marc Poliquin; Curtis Cooper
Journal:  Can J Infect Dis Med Microbiol       Date:  2014       Impact factor: 2.471

2.  Liver stiffness is associated with monocyte activation in HIV-infected Ugandans without viral hepatitis.

Authors:  Andrew D Redd; Sarah K Wendel; Mary K Grabowski; Ponsiano Ocama; Valerian Kiggundu; Francis Bbosa; Iga Boaz; Ashwin Balagopal; Steven J Reynolds; Ronald H Gray; David Serwadda; Gregory D Kirk; Thomas C Quinn; Lara Stabinski
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-08       Impact factor: 2.205

Review 3.  Hepatitis C virus infection in the human immunodeficiency virus infected patient.

Authors:  Louise Nygaard Clausen; Lene Fogt Lundbo; Thomas Benfield
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

4.  CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.

Authors:  Mark Hull; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Giguère; Pierre Côté; Marc Poliquin; Curtis Cooper
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

5.  Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?

Authors:  Evguenia Krastinova; Remonie Seng; Jerome Lechenadec; Henri Panjo; Asma Essat; Djamila Makhloufi; Martine Obadia; Louis Bernard; Cecile Goujard; Laurence Meyer
Journal:  BMC Infect Dis       Date:  2015-04-10       Impact factor: 3.090

6.  The Implications of Low Absolute CD4 Counts in Patients With Cirrhosis and Human Immunodeficiency Virus.

Authors:  Timothy Sullivan
Journal:  Open Forum Infect Dis       Date:  2016-03-29       Impact factor: 3.835

7.  CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment.

Authors:  Mark Hull; Stephen Shafran; Alex Wong; Alice Tseng; Pierre Giguère; Lisa Barrett; Shariq Haider; Brian Conway; Marina Klein; Curtis Cooper
Journal:  Can J Infect Dis Med Microbiol       Date:  2016-07-04       Impact factor: 2.471

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.